- JP-listed companies
- Kidswell Bio Corporation
- Balance sheet
Kidswell Bio Corporation (4584) Balance sheet
Market cap
¥7B
P/E ratio
KidsWell Bio develops biosimilar drugs and regenerative medicine treatments using SQ-SHED stem cells from baby teeth for pharmaceutical partners and rare disease patients.
| 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Cash and cash equivalents | - | 599 | 817 | 2,380 | 1,891 | 2,009 | 2,033 | 1,461 | 1,187 | 1,067 | 2,231 | 2,995 | 3,295 |
| Total current assets | - | 1,092 | 1,520 | 3,422 | 2,692 | 2,822 | 3,322 | 3,346 | 3,326 | 3,697 | 4,924 | 6,701 | 5,840 |
| Property, plant and equipment, net | - | 0 | 2 | 2 | 2 | 1 | 2 | 3 | 2 | 1 | 1 | 1 | 18 |
| Marketable securities, non-current | - | 50 | 165 | 276 | 275 | 273 | 249 | 563 | 155 | 173 | 138 | 283 | 212 |
| Total non-current assets | - | 54 | 174 | 284 | 333 | 330 | 270 | 588 | 177 | 198 | 161 | 308 | 248 |
| Total assets | - | 1,147 | 1,694 | 3,706 | 3,025 | 3,151 | 3,592 | 3,934 | 3,503 | 3,895 | 5,086 | 7,008 | 6,088 |
| Short-term debt | - | - | 460 | - | - | - | 25 | - | - | - | - | - | - |
| Long-term debt, current | - | - | - | - | - | - | - | - | 75 | 375 | 737 | 657 | 363 |
| Total current liabilities | - | 92 | 1,280 | 189 | 405 | 400 | 881 | 1,114 | 1,129 | 1,056 | 2,375 | 4,319 | 2,150 |
| Total non-current liabilities | - | 784 | 11 | 17 | 16 | 20 | 1,224 | 1,209 | 656 | 1,605 | 1,879 | 1,279 | 2,285 |
| Total liabilities | - | 876 | 1,291 | 206 | 421 | 420 | 2,105 | 2,324 | 1,785 | 2,661 | 4,254 | 5,598 | 4,434 |
| Retained earnings | - | -2,807 | -3,594 | -4,819 | -905 | -1,761 | -9,077 | -10,079 | -10,614 | -11,287 | -12,709 | -12,730 | -1,241 |
| Stockholders' equity | 1,053 | 271 | 403 | 3,500 | 2,604 | 2,731 | 1,487 | 1,610 | 1,719 | 1,234 | 831 | 1,411 | 1,653 |